期刊文献+

Mithramycin A对肝癌Huh-7细胞增殖和基因表达的影响

Effect of Mithramycin A on the expression of genes and on cell proliferation in human liver cancer cell line Huh-7
原文传递
导出
摘要 目的:研究光辉霉素A(mithramy-cin A,MIT)对人肝癌细胞Huh-7的作用。方法:CCK-8法观察MIT对Huh-7细胞的生长抑制作用;Realtime-PCR法和蛋白质印迹法检测MIT作用后Huh-7细胞中Sp1、VEGF和c-Met表达情况。结果:MIT作用Huh-7细胞48h时细胞生长抑制作用与浓度成正相关。5×10-4μmol/L时细胞增殖的抑制率为2.9%,5μmol/L时达92.4%。随时间延长抑制率逐渐增高,作用24h时抑制率为6.15%,60h达72.65%。半数抑制浓度(IC50)为60.12nmol/L。与对照组Sp1mRNA表达量(1.4599±0.2696)相比,其表达量与浓度有关,500nmol/L时其表达量(0.2743±0.1043)下降约为81.21%,P=0.0027。且其表达量与时间有关,与表达量(1.459856±0.269603)相比,加药72h时其表达量(0.430778±0.125143)明显下降,P=0.0034。VEGF和c-Met的mRNA表达量变化有一个相同的趋势,随浓度和时间增加表达逐渐下调。MIT对Sp1、VEGF和c-Met在蛋白水平的表达有抑制作用。结论:MIT对Huh-7细胞有明显的生长抑制作用。MIT能抑制人肝癌Huh-7细胞Sp1及其下游基因表达。 OBJECTIVE:To study the effect of Mithramycin A(MIT) on cell proliferation and gene variation of Huh-7. METHODS:Cell growth was analyzed by CCK-8 assay. Real time-PCR and Western-blot methods were used to detect expression of Sp1,VEGF and c-Met after Huh-7 cells were treated with MIT. RESULTS:When treated with 5×10-4 μmol/L MIT,for 48 h the inhibition rate of cell proliferation was 2.9%. Treated with 5 μmol/L MIT,and it was 92.4%. It suggested that MIT inhibited the cell growth in a dose-dependent manner. Huh-7 cells cells were treated with 5×10-1 μmol/L MIT after different time. After 24 hours' treatment it was 6.15%. After 60 hours' treatment it was 72.65%. It suggested that MIT inhibited the cell growth in a time-dependent manner. The IC50 value of MIT for Huh-7 cells was 60.12 μmol/L. Sp1 mRNA expression showed a marked downregulation in 500 nmol/L group (0.274 3±0.104 3) compared with controlled group (1.459 9±0.269 6,P=0.002 7). Meanwhile,It showed a marked downregulation in 72 h group (0.430 778±0.125 143) compared with 0 h group (1.459 856±0.269 603,P=0.003 4). It suggested that Sp1 mRNA expression was assoiated with MIT in a dose-dependent and time-dependent manner.The trend of mRNA expression of VEGF and c-Met was in the same way.Treatment with MIT suppress the expression of Sp1 protein and its downstream target genes VEGF and c-Met. CONCLUSIONS:Mithramycin A could inhibit the cell growth. Treatment with MIT suppressed the expression of Sp1 and its downstream target genes in human liver cancer cell line Huh-7.
出处 《中华肿瘤防治杂志》 CAS 2009年第24期1917-1921,共5页 Chinese Journal of Cancer Prevention and Treatment
基金 上海市浦江人才计划项目(06PJ14096) 上海市科学技术委员会资助项目(054119628) 上海市浦东新区卫生系统重点学科项目(PWZXK2007-06)
关键词 肝肿瘤 普卡霉素 原癌基因蛋白质C-MET 受体 血管内皮生长因子 liver neopalsms plicamycin proto-oncogene protein c-met receptors vascular endothelial grwoth factor
  • 相关文献

参考文献15

  • 1Parkin D M, Bray F, FerLay J, et al. Global cancer statistics, 2002[J]. CA CancerJ Clin, 2005, 55(2) :74-108.
  • 2李凯.原发性肝癌的内科治疗[J].中华肿瘤防治杂志,2006,13(4). 被引量:4
  • 3Remsing L L, Bahadoro H R, Carhone G M, et al. Inhibition of c-src transcription by mithramycin: structure-activity relationships of biosynthetically produced mithrarnycin analogues using the c-src promoter as target[J]. Biochemistry, 2003, 42(27):8313-8324.
  • 4Xie K P, Wei D Y, Huang S Y. Transcriptional anti-angiogene sis therapy of human pancreatic cancer [J]. Cytokine Growth Factor Rev, 2006, 17(3):147-156.
  • 5Safe S, Abdelrahim M. Sp transcription factor family and its role in cancer[J]. Eur J Cancer,2005,41(16) :2438-2448.
  • 6米登海,易继林,刘恩宇,李兴睿.血管内皮生长因子与抑癌基因PTEN在肝细胞癌组织中表达及临床意义[J].中华肿瘤防治杂志,2006,13(15):1158-1162. 被引量:16
  • 7Srivatanakul P, Sriplung H, Deerasamee S. Epidemiology of liv er cancer: an overview[J]. Asian Pac J Cancer Prey, 2004, 5(2) : 118-125.
  • 8Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor[J]. J Biol Chem, 1991, 266(18): 11947 -11954.
  • 9Liu Y H. The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization [J]. Gene, 1998,215(1) :159-169.
  • 10Leroy I, Laurent G, Quillel-Mary A. Mithramycin a activates fas death pathway in leukemic cell lines[J]. Apoptosis, 2006, 11(1) :113-119.

二级参考文献23

  • 1Wei Wang~1 Shu-Kui Qin~1 Bao-An Chen~2 Hui-Ying Chen~1 1 Chinese PLA Cancer Center,Chinese PLA 81 Hospital,Nanjing 210002,Jiangshu Province,China2 Affliliated Zhongda Hospital of Southeast University Medical College,Nanjing 210087,Jiangsu Province,China.Experimental study on antitumor effect of arsenic trioxide in combination with cisplatin or doxorubicin on hepatocellular carcinoma[J].World Journal of Gastroenterology,2001,7(5):702-705. 被引量:50
  • 2杨静悦,任军,白俊,刘都户,范黎,斯小明,腾增辉,杨文涛.HBsAg基因修饰的树突状细胞体外诱导抗HepG2.2.15特异性细胞毒作用[J].癌症,2004,23(8):914-917. 被引量:2
  • 3Xiao-YuYin Ming-DeLü Li-JianLiang Jia-MingLai Dong-MingLi MingKuang.Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma[J].World Journal of Gastroenterology,2005,11(16):2526-2529. 被引量:9
  • 4Raftopoulou M, Etienne Manneville S, Self A, et al. Regulation of cell migration by the C2 domain of the tumor suppressor PTEN[J].Science, 2004, 303(5661):1179-1181.
  • 5Weis S M, Cheresh D A. Pathophysiological consequences of VEGF induced vascular permeability [J].Nature, 2005, 437(7058) :497-504.
  • 6Washing tonK, Mass of liver. In: MillsSE, eds. Strernberg's diagnostic surgical pathology[M].4th ed. Philadcphia: Lippincott Williams & Wilkins, 2004 : 1757.
  • 7Tateishi R, Yoshida H, Shiina S, et al. Proposal of a new prognostic model for hcpatoccllular carcinoma: an analysis of 403 paticnts[J].Gut, 2005, 54(3):419-425.
  • 8Pawlik T M, Poon R T, Abdalla E K, et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma[J].Arch Sur, 2005, 140(5) :450-457.
  • 9Weidner N. Tumoural vascularity as a prognostic factor in canccr patients: the evidence continues to grow[J].J Pathol, 1998,184(2):119-122.
  • 10Fidlcr I J. The pathogenesis of cancer metastasis: the'seed and soil'hypothcsis revisited[J].Na Rev, Cancer, 2003, 3(6): 453-458.

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部